Conclusion:
TIF considered patient with hemoglobinopathies in the vulnerable
categories for COVID-19 complication and emphasized that those patients
need extra precaution during their recurrent visits to the health care
facilities. Mainly due to the lack of current evidence. However,
published literature showed a favorable outcome on the majority of
thalassemia patients who had COVID-19 infection. However, no data was
found regarding the recurrence of this infection. We suggest that all
physician should screen those patients for COVID-19 whenever the visited
the hospital as they might develop asymptomatic recurrence and even
though the clinical course seems to be smooth, screening is essential to
control this pandemic and protect this vulnerable population as their
outcome still unpredictable, thus offering them close monitoring and
controlling their comorbidities.